These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 6708126)

  • 21. The effect of C3 levels on yeast opsonization by normal and pathological sera: identification of a complement independent opsonin.
    Kerr MA; Falconer JS; Bashey A; Beck JS
    Clin Exp Immunol; 1983 Dec; 54(3):793-800. PubMed ID: 6652976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Humoral components of host defense in sickle cell disease during painful crisis and asymptomatic periods.
    Bjornson AB; Lobel JS; Lampkin BC
    J Pediatr; 1980 Feb; 96(2):259-62. PubMed ID: 7351591
    [No Abstract]   [Full Text] [Related]  

  • 23. [Studies on an extract from Haemophilus influenzae type a. II.--Phagocytic capacity of sera obtained from rabbits immunized by this bacterial extract (author's transl)].
    Raichvarg D; Brossard C; Agneray J
    Pathol Biol (Paris); 1980 May; 28(5):299-303. PubMed ID: 6992066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The antisickling role of uric acid in sickle cell disease.
    Ekeke GI; Nduka N
    Trop Geogr Med; 1987 Apr; 39(2):152-6. PubMed ID: 3629708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The key role of peptidoglycan in the opsonization of Staphylococcus aureus.
    Peterson PK; Wilkinson BJ; Kim Y; Schmeling D; Douglas SD; Quie PG; Verhoef J
    J Clin Invest; 1978 Mar; 61(3):597-609. PubMed ID: 641141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opsonic requirements for intravascular clearance after splenectomy.
    Hosea SW; Brown EJ; Hamburger MI; Frank MM
    N Engl J Med; 1981 Jan; 304(5):245-50. PubMed ID: 7442756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of C3b/C3bi opsonization and chemiluminescence with selected yeasts and bacteria using sera of different opsonic potential.
    Turner MW; Grant C; Seymour ND; Harvey B; Levinsky RJ
    Immunology; 1986 May; 58(1):111-5. PubMed ID: 3519441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies.
    Burton RL; Nahm MH
    Clin Vaccine Immunol; 2006 Sep; 13(9):1004-9. PubMed ID: 16960111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Opsonization of Salmonella enteritidis lipopolysaccharide in sickle cell disease.
    Field RJ; Overturf GD; Strunk R
    Pediatr Res; 1981 Feb; 15(2):107-11. PubMed ID: 7019833
    [No Abstract]   [Full Text] [Related]  

  • 30. Aging reduces the functionality of anti-pneumococcal antibodies and the killing of Streptococcus pneumoniae by neutrophil phagocytosis.
    Simell B; Vuorela A; Ekström N; Palmu A; Reunanen A; Meri S; Käyhty H; Väkeväinen M
    Vaccine; 2011 Feb; 29(10):1929-34. PubMed ID: 21236231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of humoral and phagocytic defenses against Streptococcus pneumoniae serotypes 1 and 3.
    Fine DP; Kirk JL; Schiffman G; Schweinle JE; Guckian JC
    J Lab Clin Med; 1988 Oct; 112(4):487-97. PubMed ID: 3171357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alternative complement pathway activity in sera from patients with sickle cell disease.
    Koethe SM; Casper JT; Rodey GE
    Clin Exp Immunol; 1976 Jan; 23(1):56-60. PubMed ID: 816581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Yeast opsonization and phagocytosis studied by a visual assay and measurement of neutrophil chemiluminescence.
    Vernon J; Kemp AS; Van Asperen PP; Worsdall P; Roy LP
    J Clin Lab Immunol; 1984 Jun; 14(2):93-7. PubMed ID: 6748051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum opsonins of control children of different ages.
    Pereira HA; Hosking CS
    Aust Paediatr J; 1983 Mar; 19(1):23-6. PubMed ID: 6870697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver function and the diagnostic significance of conjugated cholic acid and chenodeoxycholic acid in serum of African patients with sickle cell disease.
    Bolarin DM
    Acta Trop; 1983 Dec; 40(4):359-64. PubMed ID: 6142634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of penicillin-nonsusceptible Streptococcus pneumoniae in nasopharyngeal cultures from patients with sickle cell disease.
    Sakhalkar VS; Sarnaik SA; Asmar BI; Conner-Warren R; Shurney W; Abdel-Haq NM
    South Med J; 2001 Apr; 94(4):401-4. PubMed ID: 11332906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Opsonic activity of immunoglobulin prepared for intravenous use.
    Hetherington SV; Giebink GS
    J Lab Clin Med; 1984 Dec; 104(6):977-86. PubMed ID: 6502004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinetic studies of phagocytosis. III. The complement-dependent opsonic and anti-opsonic effects of normal and sle sera.
    Håkansson L; Hällgren R; Venge P
    Immunology; 1982 Sep; 47(1):91-9. PubMed ID: 6981589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defective yeast opsonisation and functional deficiency of complement in sickle cell disease.
    Larcher VF; Wyke RJ; Davis LR; Stroud CE; Williams R
    Arch Dis Child; 1982 May; 57(5):343-6. PubMed ID: 7092289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Opsonization of pneumococci. I. Heat-labile serum activity other than complement is required for killing by human polymorphonuclear leukocytes.
    Guckian JC; Christensen GD; Schweinle JE; Fine DP
    J Immunol; 1981 Oct; 127(4):1659-65. PubMed ID: 7276577
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.